Adenosine A2A receptor antagonists as new agents for the treatment of Parkinson's disease
- 1 October 1997
- journal article
- review article
- Published by Elsevier in Trends in Pharmacological Sciences
- Vol. 18 (9), 338-344
- https://doi.org/10.1016/s0165-6147(97)01096-1
Abstract
No abstract availableKeywords
This publication has 41 references indexed in Scilit:
- Parkinson's disease: prospects for improved drug therapyTrends in Pharmacological Sciences, 1997
- Pharmacology of adenosine A2A receptorsTrends in Pharmacological Sciences, 1996
- Dual Signalling by the Adenosine A2a Receptor Involves Activation of Both N‐ and P‐Type Calcium Channels by Different G Proteins and Protein Kinases in the Same Striatal Nerve TerminalsJournal of Neurochemistry, 1996
- Striatal interneurones: chemical, physiological and morphological characterizationTrends in Neurosciences, 1995
- Induction of apoptosis in catecholaminergic PC12 cells by L-DOPA. Implications for the treatment of Parkinson's disease.JCI Insight, 1995
- Dopamine Neurotoxicity: Inhibition of Mitochondrial RespirationJournal of Neurochemistry, 1995
- (E)-1,3-Dialkyl-7-methyl-8-(3,4,5-trimethoxystyryl)xanthines: potent and selective adenosine A2 antagonistsJournal of Medicinal Chemistry, 1992
- D 1 and D 2 Dopamine Receptor-regulated Gene Expression of Striatonigral and Striatopallidal NeuronsScience, 1990
- Neurotransmitters and neuromodulators in the basal gangliaTrends in Neurosciences, 1990
- Drug treatment in Parkinson's disease.BMJ, 1984